Singapore, March 2 -- China-based WuXi XDC Cayman Inc. (WuXi XDC), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) andother bioconjugates, has announced a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform.

Earendil Labs is an AI-powered biotech company focused on researching and developing next-generation innovative biologics for the treatment of autoimmune diseases, cancer, and other conditions with unmet medical needs.

This collaboration marks the establishment of a robust strategic partnership aimed at accelerating the development of next-generation ADCs by synergistically combining...